Vestal Point Capital LP Has $42.79 Million Holdings in Immatics (NASDAQ:IMTX)

Vestal Point Capital LP raised its position in Immatics (NASDAQ:IMTX) by 36.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,750,000 shares of the company’s stock after purchasing an additional 1,000,000 shares during the period. Immatics accounts for 3.2% of Vestal Point Capital LP’s investment portfolio, making the stock its 9th biggest position. Vestal Point Capital LP’s holdings in Immatics were worth $42,788,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD boosted its stake in Immatics by 38.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,225,360 shares of the company’s stock valued at $33,899,000 after buying an additional 891,191 shares during the period. HighVista Strategies LLC purchased a new stake in shares of Immatics in the 2nd quarter valued at about $904,000. Frazier Life Sciences Management L.P. bought a new stake in shares of Immatics during the 2nd quarter valued at about $13,392,000. abrdn plc purchased a new position in shares of Immatics during the third quarter worth about $2,657,000. Finally, Perceptive Advisors LLC increased its position in shares of Immatics by 76.5% in the second quarter. Perceptive Advisors LLC now owns 8,086,159 shares of the company’s stock worth $93,961,000 after purchasing an additional 3,503,750 shares during the last quarter. 64.41% of the stock is currently owned by hedge funds and other institutional investors.

Immatics Price Performance

Immatics stock opened at $7.91 on Friday. The firm has a fifty day simple moving average of $9.54 and a two-hundred day simple moving average of $11.07. Immatics has a twelve month low of $7.46 and a twelve month high of $13.77.

Analyst Upgrades and Downgrades

IMTX has been the subject of a number of research reports. Piper Sandler began coverage on shares of Immatics in a research note on Monday, October 7th. They issued an “overweight” rating and a $19.00 price target for the company. The Goldman Sachs Group upgraded shares of Immatics to a “strong-buy” rating in a research report on Monday. Cantor Fitzgerald restated an “overweight” rating on shares of Immatics in a research report on Thursday, September 5th. Finally, Bank of America cut their price objective on Immatics from $16.00 to $15.00 and set a “buy” rating for the company in a report on Tuesday, November 19th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $16.67.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.